Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies.

- Running title: SARS-CoV-2 Western immunoblotting. 4
- Edouard, S. 1,2, Jaafar, R. 1,2, Orain, N. 1, Parola, P. 1,3, Colson, P. 1,2 6
- La Scola, B.<sup>1,2</sup>, Fournier, P-E.<sup>1,3</sup>, Raoult, D.<sup>1,2</sup>, Drancourt, M.<sup>1,2</sup>\* 7

## Affiliations:

1

2

3

5

8

9

13

17

20

- <sup>1</sup> IHU-Méditerranée Infection, Marseille, France 10
- <sup>2</sup> Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France 11
- <sup>3</sup> Aix Marseille Univ., IRD, AP-HM, SSA, VITROME, Marseille, France 12
- \*Corresponding author: Michel Drancourt, IHU Méditerranée Infection, 19-21 14
- boulevard Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 15
- 413 732 402; email: michel.drancourt@univ-amu.fr 16
- Keywords: SARS-CoV-2, COVID-19, cross-reactivity, serology, automated Western 18
- immunoblotting 19
- Word count: 2475 words 21

**ABSTRACT** 

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

ELISA and chemiluminescence serological assays for COVID-19 are currently incorporating only one or two SARS-CoV-2 antigens. We developed an automated Western immunoblotting as a complementary serologic assay for COVID-19. The Jess<sup>TM</sup> Simple Western system, an automated capillary-based assay was used, incorporating an inactivated SARS-CoV-2 lineage 20a strain as antigen, and IgT detection. In total, 602 sera were tested including 223 from RT-PCR-confirmed COVID-19 patients, 76 from patients diagnosed with seasonal HCoVs and 303 from coronavirus-negative control sera. We also compared this assay with the EUROIMMUN® SARS-CoV-2 IgG ELISA kit. Among 223 sera obtained from RT-PCR-confirmed COVID-19 patients, 180/223 (81%) exhibited reactivity against the nucleocapsid and 70/223 (31%) against the spike protein. Nucleocapsid reactivity was further detected in 9/76 (14%) samples collected from patients diagnosed with seasonal HCoVs and in 15/303 (5%) coronavirus-negative control samples. In the subset of sera collected more than 2 weeks after the onset of symptoms, the sensitivity was 94% and the specificity 93%, the latter value probably reflecting cross-reactivity of SARS-CoV-2 with other coronaviruses. The automated Western immunoblotting presented a substantial agreement (90%) with the compared ELISA (Cohen's Kappa=0.64). Automated Western immunoblotting may be used as a second line test to monitor exposition of people to HCoVs including SARS-CoV-2.

## 1. INTRODUCTION

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

To date, seven coronaviruses have been reported as human pathogens. including four seasonal coronaviruses (Alphacoronavirus 229E and NL63 and Betacoronavirus HKU1 and OC43) here referred to as HCoVs, which are associated to mild-to-severe upper and lower respiratory tract infections (1). Two other betacoronaviruses that caused severe acute respiratory syndrome in 2002 in China (SARS-CoV) and the Middle East Respiratory Syndrome in 2012 in Saudi Arabia (MERS-CoV) (2); and the Betacoronavirus SARS-CoV-2 that is the agent of the COVID-19 pandemic has been demonstrated to infect a variety of animals and humans (3). The latter is phylogenetically closely related to HCoV-HKU1 and presents a high sequence homology with SARS-CoV (2). Serological assays used to explore exposition to seasonal HCoVs have previously indicated cross-immunity between all coronaviruses (4-6). SARS-CoV-2 exhibits several antigens eliciting a serological response in COVID-19 patients. including spike glycoprotein, its N-terminal (S1) and C-terminal (S2) subunits as well as nucleocapsid (7). Most of routinely used serological COVID-19 assays incorporated only one recombinant protein (8–10). Second generation assays are combining two antigens to increase sensitivity and mostly specificity (7, 11). We developed an automated Western immunoblotting (AWB) assay in order to characterize serological responses to SARS-CoV-2 and the potential crossreactivity with HCoVs. 2. PATIENTS AND METHODS **Serum sample collections.** A first set of 27 serum samples from 27 different patients with RT-PCR-documented COVID-19 (12), collected at least 2 weeks after

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

the onset of symptoms were incorporated as a positive control group. All of them presented IgG titer ≥ 1:100 using in-house indirect immunofluorescence assay (IFA) (13). Of these, 16 serum samples were used for conventional immunoblotting including 3 samples exhibiting low (1:200), moderate (1:800) and high (1:3,200) IgG titers using IFA that were used to fix optimal conditions to be used for AWB (antigen, serum and secondary antibodies concentrations). One serum collected in 2018, before the onset of COVID-19 (negative RT-PCR for HCoVs on homologous respiratory specimen) was included as negative control. As for AWB, 223 serum samples (including the 27 serum samples described above) collected from 223 different RT-PCR-confirmed COVID-19 patients were incorporated as a positive control group. Twenty-seven of these sera were tested for antibodies to the recombinant S1 protein by EUROIMMUN® SARS-CoV-2 IgG ELISA (Euroimmun, Bussy Saint-Martin, France) performed using the Elispeed DUO system (Euroimmun) according to the manufacturer's recommendations. The ratio (AUC sample/AUC calibrator) was interpreted as follows: <0.8 negative; ≥0.8 to <1.0 undetermined; ≥1.1 positive. We considered undetermined results as negative for statistical analyses. A negative control group (37 serum samples) consisted of (i) 10 serum sampled obtained less than 5 days after the onset of symptoms) in patients presenting high viral loads of SARS- CoV-2 (Ct values < 20); (ii) 14 sera from asymptomatic healthcare workers largely exposed to the virus but exhibiting negative results for RT-PCR and serology by IFA for SARS-CoV-2 during follow-up; and (iii) 13 sera from patients collected in 2019 before the pandemic and harbouring negative RT-PCR results for the 4 HCoVs in their nasopharyngeal specimens. These 37 serum samples were also all tested by ELISA. A third group of 76 serum samples was retrieved from patients diagnosed with seasonal coronavirus infections (HCoV-

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

NL63 (n=19), HCoV-OC43 (n=21), HCoV-229E (n=8) and HCoV-HKU1 (n=28)) and were collected at least 2 weeks after the diagnosis, of which 45 were also tested by ELISA. A fourth group of 266 sera was collected from children and adults admitted in surgery departments (n=145) and other medical units (=121) before the pandemic, of which 88 serum samples were also tested by ELISA; their HCoVs status was unknown. Altogether, 197 sera tested by ELISA, included 27 sera from COVID-19positive patients and 170 from COVID-19-negative patients. All sera were retrospectively tested and no sample was collected specifically for this study which was approved by our institution's ethics committee under No.2020-024. Virus growth, purification and concentration. The SARS-CoV-2 IHUMI2 strain (lineage 20a) was used as antigen as previously described (13). One liter of infected cells was collected and clarified by centrifugation at 700 x g for 10 min and by filtering the supernatant through a 0.45-um pore-sized filter and further a 0.2-um pore-sized filter. Virions were then aggregated by overnight precipitation at 4°C with 10% polyethylene glycol 8000 white flake type (PEG-8000, BioUltra, SIGMA-ALDRICH, USA) and 2.2% crystalline NaCl, with gentle swirling. Precipitated virus particles were then centrifuged at 10,000 x g for 30 min using a SORVALL Evolution centrifuge with SLA-3000 Recent 1 fixed angle rotor pre-cooled at 4°C (Kendro Laboratory Products, Newtown, USA). The pellet was resuspended with HEPESsaline (0.9% NaCl, 10 mL of 1 M HEPES, 990 mL purified water) previously vacuumsterilized through a 0.2-µm pore size membrane; swirled in the cold HEPES-saline until dissolution to avoid using pipetting as it may hurts viral spikes at this step. The resuspended pellet was then treated with a 30% sucrose cushion in 25 x 89 mm centrifuge tubes (Ultra-Clear, BECKMAN COULTER, CA, USA). Final purification

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

was achieved by ultracentrifugation at 100,000 x g for 90 min at 4°C followed by two 30-min washes with HBSS using SORVALL Discovery 90SE with Surespin 630 rotor (Kendro Laboratory Products). The final pellet was resuspended in 400 µL of HEPES-buffered saline and heat-inactivated at 65°C for 1h. Conventional Western immunoblotting. SARS-CoV-2 antigens diluted to 0.5 mg/mL were mixed (v/v) with 2X Laemmli Sample Buffer (Bio-Rad, Hercules, CA, USA) before a heating step of 5 min at 95°C. This preparation and a ladder were dispensed in wells shaped in a 5 % polyacrylamide stacking gel. The protein separation was then performed in a 10 % polyacrylamide separating gel with a Mini Trans-blot cell device (Bio-Rad) at 160 V for 90 min. After transferring proteins from the gel to a 0.45 µm-pore size nitrocellulose membrane (Bio-Rad) at 100 V and 15°C for 90 min, the membrane was left at 4°C overnight with 5% non-fat milk powder in TBS buffer. Blocked strips were incubated with sera diluted at 1:50 for 60 min. Three washes of 10 min were performed before a 90-min incubation of the strips with goat peroxidase-conjugated anti-human IgG/ IgM/IgA (Jackson ImmunoResearch, Ely, UK) diluted 1:1000. Three washes of 10 min with TBS buffer were made. Strips were put in contact with ECL Western Blotting Substrate (Promega, Madison, USA) and the reaction with secondary antibody peroxydases was revelated with a Fusion Fx chemiluminescence imaging system and analysed with the Fusion software (Vilber, Marne-la-Vallée, France). **Automated Western immunoblotting.** The Jess<sup>TM</sup> Simple Western system (ProteinSimple, San Jose CA, USA,) is an automated capillary-based size separation and nano-immunoassay system. To quantify the absolute serological response to

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

viral antigens, we followed the manufacturer's standard method for 12-230-kDa Jess separation module (SM-W004). The SARS-CoV-2 antigen (1 µg/µL) was mixed with 0.1X Sample buffer and Fluorescent 5X Master mix (ProteinSimple) to achieve a final concentration of 0.25 µg/µL in the presence of fluorescent molecular weight markers and 400 mM dithiothreitol (ProteinSimple). This preparation was denatured at 95°C for 5 minutes. Ladder (12-230-kDa PS-ST01EZ) and SARS-CoV-2 proteins were separated in capillaries as they migrated through a separation matrix at 375 volts. A ProteinSimple proprietary photoactivated capture chemistry was used to immobilize separated viral proteins on the capillaries. Patients sera diluted at a 1:2 were added and incubated for 60 min. After a wash step, goat HRP-conjugated antihuman IgG/IgM/IgA antibodies (Jackson ImmunoResearch) diluted 1:500 was added for 30 min. The chemiluminescent revelation was established with peroxyde/luminol-S (ProteinSimple). Digital image of chemiluminescence of the capillary was captured with Compass Simple Western software (version 4.1.0, Protein Simple) that calculated automatically heights (chemiluminescence intensity), area and signal/noise ratio. Results could be visualized as electropherograms representing peak of chemiluminescence intensity and as lane view from signal of chemiluminescence detected in the capillary. An internal system control was included in each run.

**Statistical analysis.** ROC curves were performed using XL stat. The agreement rate and Cohen's Kappa value were determined for agreement between ELISA and AWB. For data comparisons and statistical analyses, the Fisher's exact test, Chisquared test, Mann-Witney test and standard statistical software (GraphPad Prism v7) were used. A p-value < 0.05 was considered statistically significant.

3. RESULTS

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

Fixing automated Western immunoblotting parameters. Protein profiles of the purified SARS-CoV-2 antigen and uninfected Vero cells were verified on silverstained 2-D gel. As expected, the viral specific and major dominant proteins were N. S, S1 and S2 proteins at 42, 170, 110 and 90 kDa, respectively. All 16 serum samples collected from 16 different COVID-19 patients exhibited reactivity against the nucleocapsid and spike proteins. Parameter optimization to translate these data on AWB included an antigen concentration of 0.25 µg/µL, a serum dilution at 1:2 and a secondary antibody dilution of 1:500 (data not shown). In these conditions, AWB of positive serum samples yielded a prominent 56-kDa band interpreted as the nucleocapsid and a 217-kDa band interpreted as the spike protein (Figure S1). Higher molecular weight values observed with AWB than with SDS-PAGE were due to the different composition of gel in the capillaries. In total, the 16 sera from COVID-19 patients tested with conventional and AWB gave similar results except that AWB failed to detect the spike protein in one sample. Further, AWB yielded significant higher S/N ratio, pick height and area under curve for the nucleocapsid (p < 0.0001) and spike proteins (p < 0.0001) in the 27 serum samples from COVID-19 patients than in 37 serum samples collected in negative control patients (Table 1). The S/N ratio presented higher Youden Index for nucleocapsid detection, being therefore interpreted as the most pertinent parameter to interpret AWB results. Optimal threshold for the S/N ratio of 110.4 conferred a 96.3% sensitivity and 94.6% specificity for the nucleocapsid detection. Determination of a cut-off to interpret results of spike protein was not useful and could be based only on presence/absence of signal with sensitivity to 66.7% and 100% specificity (Table 2).

Therefore, we further used the presence of antibodies to the nucleocapsid with S/N ratio ≥ 110.4 and/or to the spike protein, as criteria to define a positive AWB.

Automated Western immunoblotting results. AWB yielded 395/602 (66%) negative and 207/602 (34%) positive serum samples (Table 3); giving an 81% sensitivity as 181/223 COVID-19 patients were positive (nucleocapsid detected in 180/223 (76%) and spike in 67/223 (30%), respectively); and a 93% specificity as 26/379 (7%) non-COVID-19 patients were positive; applying above reported cut-off criteria (Figures 1 and 2a). Accordingly, positive (PPV) and negative predictive values (NPV) were of 87% and 89%, respectively. Sera from COVID-19 patients were collected with a median of 13 days (range 0 to 165) after the onset of symptoms. Sensitivity was 54% among sera collected less than 10 days after the onset of symptoms and increased to 94% among sera collected more than 10 days after the onset of symptoms (Figure 3). AWB had a 90% agreement with the herein compared ELISA assay (Cohen's Kappa=0.64) as the latter was positive in 22/27 (81.5%) COVID-19 patients and 6/170 (3.5%) non-COVID-19 patients, yielding a sensitivity of 81.5% and specificity of 97% (Table 4).

Detailing false-positive AWB, antibodies to the nucleocapsid were detected in 3/37 (8%) negative control serum samples. Also, 9/76 (14%) serum sampled from patients diagnosed with seasonal HCoVs, reacted with the nucleocapsid which was detected in 5/28 (18%) of patients with HCoV-HKU1, 2/19 (10.5%) with HCoV-NL63, 2/21 (9.5%) with HCoV-OC43 but in none of HCoV-229E patients (Figure 2b). In addition, one HCoV-HKU1 serum and one HCoV-NL63 serum reacted against the spike protein, increasing the number of total cross-reactions to 11/76 (14.5%) for this group. Among 266 serums sampled before the COVID-19 epidemic in France, albeit

of unknown status for HCoVs, 12/266 (4.5%) reacted against the nucleocapsid but none against the spike protein.

Most cross reactivities were detected in 46-65-year-old patients (7/63) and more than 65-year-old (4/43) patients (Figure 2c). Cross reactivity was more prevalent in subjects > 21 years (15/173) than in children  $\leq$  15 years (6/126) but this difference was not significant (p = 0.25, Fisher's exact test).

## 4. DISCUSSION

An AWB, incorporating whole SARS-CoV-2 viral particles, was demonstrate to be efficient in detecting specific antibodies against SARS-CoV-2 dual nucleocapsid and spike proteins, achieving a 87% PPV and a 89% NPV for COVID-19, in the population tested in this study. Accordingly, dual nucleocapsid and spike protein detections exhibited 81% sensitivity and 93% specificity. Indeed, the spike protein was detected in only two non-COVID-19 patients whereas the nucleocapsid protein was detected in 24 non-COVID-19 patients, including 11 patients diagnosed with HCoVs. In our study, AWB results were consistent with results obtained using a commercially ELISA incorporating recombinant spike-1 protein. The serological observations obtained in this study therefore indicated that it is worth developing next generation serological assays incorporating both the nucleocapsid and the spike proteins, in order to achieve almost 100% sensitivity and 100% specificity of SARS-CoV-2 infection, which is not the situation with first generation, commercially-available serological assays (7, 11, 14).

It should be noted that cross-reactivity was more prevalent in patients infected with other betacoronaviruses (accounting for 31% of cross-reactivity) than in patients infected with alphacoronaviruses (accounting for 12% of cross-reactivity); being

mainly supported by SARS-CoV-2 nucleocapsid (in 92% of cross-reacting serum samples); and mostly found in adult patients older than 46 years (accounting for 52% of sera with cross-reactivity). Our observations are consistent with previous reports that cross-reactions were observed with nucleocapsid while serological assays incorporating the spike protein have been reported to be more specific but less sensitive (4–6, 15–18). Cross-reactivity has been described between endemic coronaviruses and SARS-CoV-2 (19). Several studies reported the presence of antibodies reacting with SARS-CoV-2 spike and nucleocapsid proteins in serum sampled before the pandemic and in HCoVs patients (20, 21).

In a few previous reports of the described AWB (22–24), a recombinant protein was used as the antigen whereas we used purified virus antigen directly produced in the biosafety level 3 laboratory (13). This fact could explain in part the important difference of sensitivity for the spike protein compared to the nucleocapsid, in our assay. Thereby, serum dilution was a critical parameter as the spike protein was detected only for a low, 1:2 dilution of serum. Nevertheless, the herein described AWB assay demonstrated a better standardization and reproducibility than conventional Western immunoblotting, proved to be user-friendly and enabled analyzing 24 serum samples in less than 4 hours. Result interpretation was not only based on presence/absence and intensity of bands but a chemiluminescent image was automatically analyzed with software allowing noise reduction. The "virtual image" of reactions present in the capillaries could be represented by peaks on electropherogram or lane views.

In conclusion, the herein described AWB may be incorporated as a first line serological test for the diagnosis of exposure to SARS-CoV-2 if limited series have to be investigated; or as a second-line assay to confirm or exclude the diagnosis of

COVID-19 especially in patients with negative, doubtful and discrepant RT-PCR results, and may be used to measure past exposition to the virus. **ACKNOWLEDGMENTS** The authors acknowledge the contribution of the technical staff of the IHU Méditerranée Infection Laboratory. This work was supported by IHU Méditerranée Infection, Marseille, France. RJ benefits from a PhD grant by fondation Mediterranée Infection, Marseille, France. **FINANCIAL SUPPORT** This study was funded by ANR-15-CE36-0004-01 and by ANR "Investissements d'Avenir" Méditerranée Infection 10-IAHU-03. **DECLARATION OF COMPETING INTEREST** None to declare.

REFERENCES

306

285 Zimmermann P, Curtis N. 2020. Coronavirus Infections in Children Including 1. 286 COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, 287 Treatment and Prevention Options in Children. Pediatr Infect Dis J 39:355–368. 288 Coronaviridae Study Group of the International Committee on Taxonomy of 289 2. Viruses. 2020. The species Severe acute respiratory syndrome-related 290 coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 291 292 5:536-544. 3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu 293 R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel 294 Coronavirus Investigating and Research Team. 2020. A Novel Coronavirus from 295 Patients with Pneumonia in China, 2019. N Engl J Med 382:727–733. 296 4. Maache M. Komurian-Pradel F. Rajoharison A. Perret M. Berland J-L. Pouzol S. 297 Bagnaud A, Duverger B, Xu J, Osuna A, Paranhos-Baccalà G. 2006. False-298 positive results in a recombinant severe acute respiratory syndrome-associated 299 coronavirus (SARS-CoV) nucleocapsid-based western blot assay were rectified 300 by the use of two subunits (S1 and S2) of spike for detection of antibody to 301 SARS-CoV. Clin Vaccine Immunol 13:409–414. 302 Woo PCY, Lau SKP, Wong BHL, Chan K-H, Hui W-T, Kwan GSW, Peiris JSM, 5. 303 304 Couch RB, Yuen K-Y. 2004. False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid 305

enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E

307 rectified by Western blotting with recombinant SARS-CoV spike polypeptide. J Clin Microbiol 42:5885-5888. 308 309 6. Che X-Y, Qiu L-W, Liao Z-Y, Wang Y, Wen K, Pan Y-X, Hao W, Mei Y-B, Cheng VCC, Yuen K-Y. 2005. Antigenic cross-reactivity between severe acute 310 respiratory syndrome-associated coronavirus and human coronaviruses 229E 311 and OC43. J Infect Dis 191:2033-2037. 312 Burbelo PD. Riedo FX. Morishima C. Rawlings S. Smith D. Das S. Strich JR. 7. 313 Chertow DS, Davey RT, Cohen JI. 2020. Sensitivity in Detection of Antibodies 314 to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome 315 Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect Dis 222:206-316 213. 317 Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, 8. 318 Adriano A. Beese S. Dretzke J. Ferrante di Ruffano L. Harris IM, Price MJ. 319 Dittrich S, Emperador D, Hooft L, Leeflang MM, Van den Bruel A, Cochrane 320 COVID-19 Diagnostic Test Accuracy Group. 2020. Antibody tests for 321 identification of current and past infection with SARS-CoV-2. Cochrane 322 Database Syst Rev 6:CD013652. 323 Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu 324 9. C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q-W, Xu S-Y, Zhu H-D, Xu Y-325 C, Jin Q, Sharma L, Wang L, Wang J. 2020. Profiling Early Humoral Response 326 to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis 71:778-327 785. 328

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

10. Liu Z-L, Liu Y, Wan L-G, Xiang T-X, Le A-P, Liu P, Peiris M, Poon LLM, Zhang W. 2020. Antibody Profiles in Mild and Severe Cases of COVID-19. Clin Chem 66:1102-1104. 11. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, Goldgof GM, Levine AG, Bapat SP, Stramer SL, Esensten JH, Hightower AW, Bern C, Wu AHB. 2020. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin Infect Dis https://doi.org/10.1093/cid/ciaa979. 12. Amrane S, Tissot-Dupont H, Doudier B, Eldin C, Hocquart M, Mailhe M, Dudouet P, Ormières E, Ailhaud L, Parola P, Lagier J-C, Brouqui P, Zandotti C, Ninove L, Luciani L, Boschi C, La Scola B, Raoult D, Million M, Colson P, Gautret P. 2020. Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot. Travel Med Infect Dis 101632. 13. Edouard S, Colson P, Melenotte C, Di pinto Fabrizio, Thomas Laurence, La Scola B, Million M, Tissot-Dupont, Gautret philippe, Stein A, Brougui P, Parola P, Lagier J-C, Raoult D, Drancourt M. 2020. Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France, Eur J Clin Microbiol Infect Dis 1-11 https://doi.org/10.1007/s10096-020-04104-2.

14. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. 2020. Brief clinical 350 evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J Clin Virol 351 352 129:104480. 15. Meyer B, Drosten C, Müller MA. 2014. Serological assays for emerging 353 coronaviruses: challenges and pitfalls. Virus Res 194:175–183. 354 16. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu 355 Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. 2020. Characterization of 356 spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-357 reactivity with SARS-CoV. Nat Commun 11:1620. 358 17. Marien J, Michiels J, Heyndrickx L, Kerkhof K, Foque N, Widdowson M-A, 359 Desombere I, Jansens H, Van Esbroeck M, Arien KK. 2020. Evaluating SARS-360 CoV-2 spike and nucleocapsid proteins as targets for IgG antibody detection in 361 severe and mild COVID-19 cases using a Luminex bead-based assay. medRxiv 362 preprint 2020. https://doi.org/10.1101/2020.07.25.20161943. 363

- 18. Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, 364
- Vandecandelaere P, Indevuyst C, Depypere M, Desmet S, André E, Van Ranst 365
- M, Lagrou K, Vermeersch P. 2020. Antibody response against SARS-CoV-2 366
- 367 spike protein and nucleoprotein evaluated by four automated immunoassays
- and three ELISAs. Clin Microbiol Infect 368
- https://doi.org/10.1016/j.cmi.2020.07.038. 369
- 19. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan 370
- SM, Borgert BA, Moreno CA, Solomon BD, Trimmer-Smith L, Etienne V, 371
- Rodriguez-Barraquer I, Lessler J, Salje H, Burke DS, Wesolowski A, Cummings 372

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

DAT. 2020. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun 11:4704. 20. Khan S, Nakajima R, Jain A, de Assis RR, Jasinskas A, Obiero JM, Adenaiye O. Tai S. Hong F. Milton DK, Davies H, Felgner PL, Prometheus Study Group. 2020. Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray. BioRxiv Prepr Serv Biol https://doi.org/10.1101/2020.03.24.006544. 21. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, Wrobel AG, Benton DJ, Roustan C, Bolland W, Thompson R, Agua-Doce A, Hobson P, Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Thomson K, Sanchez E, Shin GY, Spyer MJ, Joshi D, O'Reilly N, Walker PA, Kjaer S, Riddell A, Moore C, Jebson BR, Wilkinson M, Marshall LR, Rosser EC, Radziszewska A, Peckham H, Ciurtin C, Wedderburn LR, Beale R, Swanton C, Gandhi S, Stockinger B, McCauley J, Gamblin SJ, McCoy LE, Cherepanov P, Nastouli E, Kassiotis G. 2020. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science https://doi.org/10.1126/science.abe1107. 22. Yeh H-Y, Serrano KV, Acosta AS, Buhr RJ. 2016. Production of recombinant Salmonella flagellar protein, FlgK, and its uses in detection of anti-Salmonella antibodies in chickens by automated capillary immunoassay. J Microbiol Methods 122:27–32. 23. Fourier A, Dorey A, Perret-Liaudet A, Quadrio I. 2018. Detection of CSF 14-3-3 Protein in Sporadic Creutzfeldt-Jakob Disease Patients Using a New Automated Capillary Western Assay. Mol Neurobiol 55:3537–3545.

24. Kodani M, Martin M, de Castro VL, Drobeniuc J, Kamili S. 2019. An Automated Immunoblot Method for Detection of IgG Antibodies to Hepatitis C Virus: a Potential Supplemental Antibody Confirmatory Assay. J Clin Microbiol 57.

Figure Legends. Figure 1. Drawing illustrating (a) overall results of automated Western immunoblotting of 602 sera (b) results comparison with commercially available ELISA in 197 sera. Figure 2. Signal/noise ratio for the detection of nucleocapsid with automated Western immunoblotting: (a) in 602 sera collected from 6 different groups of patients (b) in 76 sera collected from non-COVID-19, HCoVs infected patients (c) in 342 sera collected before the COVID-19 pandemic, classified by age-group. Figure 3. Automated Western immunoblotting detection of anti-SARS-CoV-2 antibodies: positive and negative sera according to delay after the onset of symptoms. The curve represents the proportion of positive sera (%).

Figure S1. Strips of conventional western immunoblotting (a) and lane view of automated Western immunoblotting (b) incubated with serum collected from one COVID-19 positive patient quoted "+" and serum collected from one non COVID-19 patient quoted "-". The first lane represents the molecular mass marker in kDa. (c) chromatogram of chemiluminescence intensity detected by Jess<sup>TM</sup> Simple Western in the capillaries on positive (blue) and negative (green) sera.

Table 1. Automated Western immunoblotting results of 27 sera from COVID-19-positive patients and 37 sera from negative controls used to fix automated Western immunoblotting parameters. (Results expressed as median with 25 and 75 percentile).

	Early sera from COVID-19- positive patients (n=10)	sera from negative HCoVs patients collected before the pandemic (n=13)	sera from healthcare workers highly exposed to SARS-CoV-2 (n=14)	All	sera from COVID-19-positive patients (n=27)	
Nucleocapside (56 kDa)						
S/N ratio	44 (29.98-64.4)	62.1 (33-78.7)	49.85 (34.95-70.95)	49.85 (34.95- 70.95)	421 (214.1-666.8)	
Height	6511 (5674-7729)	8854 (6428- 12995)	4934 (4397-5605)	6100 (4586-9813)	64065 (32338-121517)	
Area	82169 (65588- 94895)	124541 (84495- 147319)	67780 (61427-76234)	79634 (66110- 128111)	839470 (524393-1597656)	
Spike (217 kDa)						
S/N	0	0	0	0	27.9 (0-43.1)	
Height	0	0	0	0	3174 (0-8621)	
Area	0	0	0	0	40699 (0-182108)	

Table 2. Sensitivity and specificity of automated Western immunoblotting determined with 27 sera from COVID-19-positive patients and 37 sera from non COVID-19 patients.

n=64	AUC	Youden index	Optimal Cut-off value	Sensitivity (%)	Specificity (%)	True positive (nb)	True negative (nb)	False positive (nb)	False negative (nb)
Nucleocapside									
S/N	0.975	0.907	110.4	96.3	94.6	26	35	2	1
Height	0.982	0.885	24922	88.9	100	24	37	0	3
Area	0.970	0.885	287005	88.9	100	24	37	0	3
Spike									
S/N	0.833	0.667	0	66.7	100	18	37	0	9
Height	0.833	0.667	0	66.7	100	18	37	0	9
Area	0.833	0.667	0	66.7	100	18	37	0	9


AUC= area under the curve.


 $Table \ 3. \ Results \ of \ automated \ Western \ immunoblotting \ including \ the \ 602 \ sera \ tested.$ 


	Negative controls							
	Early sera from COVID- 19 positive patients (n=10)	Sera from negative HCoVs patients collected before the pandemic (n=13)	Sera from healthcare workers highly exposed to SARS-CoV- 2 (n=14)	All (n=37)	Sera from patients diagnosed with others HCoVs (n=76)	Sera collected before the pandemic from patients with unknown status for HCoVs (n=266)	Sera from COVID-19 positive patients (n=223)	Total (n=602)
Positive sera (Nb,%)								
Nucleocapside reactivity	1 (10%)	0 (0%)	2 (14)	3 (8)	9 (12)	12 (4.5%)	180 (81)	204 (34)
Spike reactivity	0	0	0	0	2 (3)	0	67 (30)	69 (11%)
Total	1 (10%)	0 (0%)	2 (14)	3 (8)	11 (14.5)	12 (4.5%)	181 (81)	207 (34%)

Table 4. Comparison between automated Western immunoblotting and commercial SARS-CoV-2 IgG ELISA on 197 sera.

	AWB IgT Nb (%)	ELISA IgG Nb (%)
Sera from COVID-19 positive patients (n=27)	27 (100%)	22 (81%)
Sera from negative control group (n=37)	3 (8%)	0
Early sera from COVID-19 positive patients (n=10)	1 (10%)	0
Sera from healthcare workers highly exposed to SARS-		
CoV-2 (n=14)	2 (14%)	0
Sera from negative HCoVs patients collected before the		
pandemic (n=13)	0	0
Sera from patients diagnosed with others HCoVs (n=45)	6 (13%)	0
Sera collected before the pandemic from patients with unknown status for HCoVs (n=88)	5 (6%)	6 (7%)







Nb of automated western immunoblotting

